Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
3.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Blood
; 141(3): 219-230, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095849
4.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
5.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
6.
Progressive multifocal leukoencephalopathy in multiple myeloma.
Eur J Haematol
; 110(3): 322-329, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36465014
7.
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(18): 1235-1247, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37403937
8.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
9.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018
10.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(10): 1317-1330, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32866432
11.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
12.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 26(10): e247-e255, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589921
13.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Blood
; 130(5): 597-605, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550039
14.
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
Am J Hematol
; 94(S1): S28-S33, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30730071
15.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Lancet Oncol
; 19(12): 1641-1653, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442502
16.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med
; 373(11): 1040-7, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352815
17.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817190
18.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Blood
; 126(20): 2284-90, 2015 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384354
19.
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Br J Haematol
; 193(4): 851-855, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713436
20.
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Clin Lymphoma Myeloma Leuk
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627181